US HHS Says Moderna Late Stage Trials Of H5N1 Likely To Start In 2025; Risk Of Bird Flu Remains Low, Vaccination Not Recommended For Any Segment; FDA Confirms Pasteurization Inactivates Milk Tainted With H5N1; CDC: 750K H5N1 Tests Available, 1.2M More Coming In Next 2-3 Months
Portfolio Pulse from Benzinga Newsdesk
The US Department of Health and Human Services (HHS) announced that Moderna's late-stage trials for the H5N1 bird flu vaccine are likely to start in 2025. The risk of bird flu remains low, and vaccination is not recommended for any segment of the population. The FDA confirmed that pasteurization inactivates milk tainted with H5N1. The CDC has 750,000 H5N1 tests available, with an additional 1.2 million tests expected in the next 2-3 months.
July 02, 2024 | 2:57 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Moderna's late-stage trials for the H5N1 bird flu vaccine are expected to start in 2025. The current low risk of bird flu and no recommendation for vaccination may limit immediate market reaction.
The announcement of future trials is a positive development for Moderna, but the low current risk of bird flu and no immediate need for vaccination may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
The broader market, represented by SPY, is unlikely to be significantly impacted by the news of Moderna's H5N1 vaccine trials or the low risk of bird flu.
The news is specific to Moderna and the H5N1 bird flu, with limited broader market implications. Therefore, SPY is expected to remain neutral in the short term.
CONFIDENCE 80
IMPORTANCE 30
RELEVANCE 20